AbbVie Inc. ABBV
Composite 57/100; the shares have moved about 27% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 29/100 — a moderate mark against it.
Quality ranks 77/100 — a strong point in its favour. Income ranks 67/100 — a moderate point in its favour. Momentum ranks 66/100 — a moderate point in its favour.
Valuation ranks 29/100 — a moderate mark against it.
What the company does AbbVie is a diversified biopharmaceutical company focused on autoimmune diseases, oncology, neuroscience, aesthetics, and specialty therapies. Key products include Skyrizi, Rinvoq, and Botox Therapeutic, with neuroscience highlighted as a growth engine.
Key financials AbbVie reports strong profitability metrics: ROE 62.3%, ROA 10.5%, and ROCE 14.2%. Gross margins are 72.8%, operating margins 40.0%, and net margins 9.8%. Revenue growth is 10.2%, while EPS growth surged 290.4%.
Stock health Sideravia scores show high quality (79.4) and momentum (73.7), with a weak valuation percentile (27.5). Profitability scores (Piotroski F-Score 8/9, Altman Z 2.42) are strong, but leverage metrics (Net debt/EBITDA 2.09) warrant attention.
Price vs fair value The stock trades at a **discount of 6.40%** to the analyst mean target of 275.39. - Neuroscience seen as a $12.7B sales driver this year (Motley Fool) - Simply Wall St notes potential for a premium despite cash flow upside - StockStory cites two positives and one skepticism factor - Recent obesity IPO headlines underscore pipeline competition (24/7 Wall St.)
Looking forward Forward P/E of 17.64 and PEG of 0.06 suggest reasonable earnings expectations. Dividend yield is 2.7% with a 62.8% payout ratio. Momentum remains positive (12m 29.16%), but valuation metrics remain stretched.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.